Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Gilead’

Regenerative Medicine: Thoughts on How to Invest in This Dynamic New Technology

Key Investment Points of this Report Regenerative medicines promises to be a (the) major technology driving the biopharma industry in coming decades. The CAR-T products are the first commercially significant products stemming from this technology, but they are just the tip of a very large iceberg. Novartis, Gilead and Celgene have gained first mover status […]

Gilead’s Acquisiton of Pharmasset Is Expensive But Great Strategic Move (GILD, $35.57)

Gilead (GILD) is certainly paying up for Pharmasset with its offer to buy the company at $137 per share ($11 billion), an 89% premium to last Friday‚Äôs close. Gilead will be paying for the acquisition with cash on hand and debt. Relative to alternatives such as investing money in short term debt instruments or doing […]